A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study

(2015) Ahmad-Samer Al-Homsi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study

(2014) Michael Wang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma

(2014) James S. Blachly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group

(2014) Annarita Conconi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells

(2014) Ion Cristóbal et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma

(2014) Y Yang et al.   LEUKEMIA

Targeting the ubiquitin proteasome system in haematological malignancies

(2013) Lisa J. Crawford et al.   BLOOD REVIEWS

Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients

(2013) Mauricette Michallet et al.   EXPERIMENTAL HEMATOLOGY

Genetic heterogeneity of diffuse large B-cell lymphoma

(2013) Jenny Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

(2011) Irene M Ghobrial et al.   LANCET ONCOLOGY

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

(2010) J. J. Wright   CLINICAL CANCER RESEARCH

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

(2010) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

(2009) N. Di Bella et al.   BLOOD

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

(2009) Owen A. O’Connor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma

(2008) Stephen M. Ansell et al.   CANCER